The SATURN trial: The value of maintenance erlotinib in patients with non-small-cell lung cancer

Future Oncology

Volumn 6, Issue 12, 2010, Pages 1827-1832

  Neal, Joel W ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

EGF receptor tyrosine kinase inhibitor; erlotinib; gefitinib; maintenance chemotherapy; non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE; PACLITAXEL; PLACEBO;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DRUG EFFICACY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650462766     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.156     Document Type: Review

References (22)

1. The Global Burden of Disease: 2004 Update. WHO Press, Switzerland (2004).
2. American Cancer Society: Cancer Facts and Figures 2010. American Cancer Society, GA, USA (2010).
3. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, MD, USA (2009).
4. Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
5. Scagliotti GV, Parikh P, Von Pawel J et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
6. Sandler A, Gray R, Perry MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
7. Shepherd FA, Dancey J, Ramlau R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000).
8. Fidias PM, Dakhil SR, Lyss AP et al.: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27(4), 591-598 (2009).
9. Hanna N, Shepherd FA, Fossella FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).
10. Ciuleanu T, Brodowicz T, Zielinski C et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 374(9699), 1432-1440 (2009).
11. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004). (Pubitemid 41103588)
12. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004). (Pubitemid 41103589)
13. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
14. Gatzemeier U, Pluzanska A, Szczesna A et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
16. Thatcher N, Chang A, Parikh P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
17. Mok TS, Wu YL, Thongprasert S et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
18. Kim ES, Hirsh V, Mok T et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
19. Cappuzzo F, Ciuleanu T, Stelmakh L et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: amulticentre, randomised, placebo-controlled Phase III study. Lancet Oncol. 11(6), 521-529 (2010).
20. Perol M, Chouaid C, Milleron BJ et al.: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin- gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 Phase III study. J. Clin. Oncol. 28(15S), Abstract 7507 (2010).
21. Kwak EL, Bang YJ, Camidge DR et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
22. Fidias P, Novell S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. DOI: 10.1200/JCO.2010.30. 7074 (2010) (Epub ahead of print)